Alternative Health Distribution LLC d/b/a CannaAid – FDA Warning Letter, Oct 7, 2022

The FDA and FTC issued a Warning Letter to CannaAid Shop after reviewing their website, cannaaidshop.com, on October 5 and 7, 2022. The agencies found that CannaAid Shop offers cannabinoid and CBD products for sale, claiming they can mitigate, prevent, treat, diagnose, or cure COVID-19. The FDA determined these products are unapproved new drugs, violating section 505(a) of the FD&C Act (21 U.S.C. § 355(a)), and are misbranded drugs under section 502 (21 U.S.C. § 352). Consequently, their introduction into interstate commerce is prohibited by sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)). The FTC also cited violations of the FTC Act (15 U.S.C. § 41 et seq.) for making unsubstantiated claims regarding COVID-19 prevention or treatment. CannaAid Shop is required to immediately cease selling these unapproved and unauthorized products and making unsubstantiated claims. They must email both the FDA and FTC within 48 hours, detailing corrective actions, plans to prevent recurrence, and supporting documentation. Failure to comply may result in legal action, including seizure, injunction, civil penalties up to $46,517 per violation, and being added to the FDA's public list of fraudulent COVID-19 product sellers.